A Study of Tildrakizumab in the Treatment of Genital Psoriasis

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to access overall treatment safety and quality of life assessed on multiple scales.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06042920` - A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis	Phase 4
Recruiting	`NCT05969223` - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis	Phase 4
Completed	`NCT02718898` - A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis	Phase 3

NCT number	NCT06029257
Study type	Observational
Source	Almirall, S.A.
Contact	Senior Director Regional Medical Affairs
Phone	+43 0 15953960
Email	medicalat@almirall.com
Status	Recruiting
Phase
Start date	November 14, 2023
Completion date	July 2025

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms